

Akebia Therapeutics, Inc.  
Form 8-K/A  
September 22, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 2054**

**Amendment No. 1**

**to**

**FORM 8-K/A**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported)**

**September 12, 2014**

**AKEBIA THERAPEUTICS, INC.**

**(Exact name of registrant as specified in charter)**

Edgar Filing: Akebia Therapeutics, Inc. - Form 8-K/A

**Delaware**  
**(State or Other Jurisdiction**

**001-36352**  
**(Commission**

**20-8756903**  
**(I.R.S. Employer**

**of Incorporation)**

**File Number)**

**Identification No.)**

**245 First Street, Suite 1100, Cambridge, Massachusetts 02142**

**(Address of Principal Executive Offices, including Zip Code)**

**(617) 871-2098**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As previously disclosed in the Current Report on Form 8-K filed by Akebia Therapeutics, Inc. (the Company ) on September 15, 2014, the Company s Board of Directors (the Board ) elected Ronald C. Renaud, Jr. as a director. Mr. Renaud was not appointed to any committee of the Board at that time. On September 18, 2014, Mr. Renaud was appointed to serve on the Company s Compensation Committee.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AKEBIA THERAPEUTICS, INC.**

By: /s/ JOHN P. BUTLER  
John P. Butler  
President and Chief Executive Officer

Date: September 22, 2014